skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

This white paper examines the landscape of new drug development and clinical trial activity in heart failure, which affects 5.8 Americans and 23 million people globally. In the past five years, just one new/novel drug has been registered with a regulatory authority for approval, and three other compounds with previous approvals in other indications such as hypertension and angina were also registered for heart failure to see where the future of treatment could lead us.